Behrooj Neda, Aziznejadroshan Parvin, Akbarian Rad Zahra, Nikbakht Hossein-Ali, Zabihi Ali
Student Research Committee, Babol University of Medical Sciences, Babol, Iran.
Non-Communicable Diseases Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.
Sci Rep. 2025 May 19;15(1):17390. doi: 10.1038/s41598-025-02309-z.
Based on the immunological properties of maternal colostrum, this study aimed to determine the effect of oropharyngeal colostrum on preventing late-onset sepsis in preterm infants. This clinical trial was conducted from May 2023 to June 2024 at Rouhani Hospital with 70 premature infants. In the control group, no colostrum was administered, while the intervention group received 0.4 ml of colostrum every three hours for seven days, with extraoral massage for better absorption. The relative risk of late-onset sepsis was 55% lower in the intervention group (RR = 0.45, 95% CI: 0.17 to 1.16). Although the difference in sepsis incidence between the groups was not statistically significant (11, 32.4% vs. 5, 14.7% infants, P = 0.086), it was clinically important. The age of achieving full enteral feeding was significantly lower in the intervention group (4.47 ± 2.33 vs. 3.24 ± 2.10 days, P = 0.025), but no significant differences were found in the age of achieving independent oral feeding, weight gain at discharge, or length of hospitalization. This study suggests that oropharyngeal colostrum may help reduce the incidence of late-onset sepsis and decrease the time to achieve full enteral feeding in preterm infants.Trial registration: IRCT, IRCT20230312057698N1. Registered 29 March 2023 prospective, https://irct.behdasht.gov.ir/trial/69281 .
基于母体初乳的免疫特性，本研究旨在确定口咽初乳对预防早产儿晚发性败血症的效果。这项临床试验于2023年5月至2024年6月在鲁哈尼医院对70名早产儿进行。对照组未给予初乳，而干预组每三小时接受0.4毫升初乳，共七天，并进行口外按摩以促进吸收。干预组晚发性败血症的相对风险降低了55%（RR = 0.45，95% CI：0.17至1.16）。尽管两组之间败血症发生率的差异无统计学意义（11名，32.4%对5名，14.7%婴儿，P = 0.086），但在临床上具有重要意义。干预组实现完全经口喂养的年龄显著更低（4.47±2.33对3.24±2.10天，P = 0.025），但在实现自主经口喂养的年龄、出院时体重增加或住院时间方面未发现显著差异。本研究表明，口咽初乳可能有助于降低早产儿晚发性败血症的发生率，并缩短实现完全经口喂养的时间。试验注册：IRCT，IRCT20230312057698N1。于2023年3月29日前瞻性注册，https://irct.behdasht.gov.ir/trial/69281 。
